Work

Neoadjuvant lenvatinib plus pembrolizumab for resectable clear-cell renal cell carcinoma (PELUR): A prospective phase 2 study.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.4541

Authors: Shimiao Zhu, Changyi Quan, Haotian Wei

Institutions: Second Hospital of Tianjin Medical University, Tianjin Medical University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410822650

Cites:

Cited by: 4

Related to: 10